BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form
Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
Robert B. Livingston, MD
eRA COMMONS USER NAME
POSITION TITLE
Professor of Medicine
Hematology/Oncology
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
and include postdoctoral training.)
DEGREE
INSTITUTION AND LOCATION
(if
YEAR(s)
FIELD OF STUDY
applicable)
University of Oklahoma, Norman, OK
B.A.
1963
History
University of Oklahoma, Oklahoma City, OK
M.D.
1967
Medicine
A. Professional Experience and Honors
Professional Experience
1967-1968
Internship, Parkland Hospital, Southwestern Medical School, Dallas, TX
1968-70
PHS, Special Assistant to Chief, National Cancer Institute, Bethesda, MD
1970-1971
Medicine Residency, University of Oklahoma, Oklahoma City, OK
1971-1973
Oncology Fellowship, University of Texas Systems Cancer Center, Houston, TX
07/73-09/73
Faculty Associate, University of Texas Systems Cancer Center, Houston, TX
09/73-03/76
Assistant Professor, University of Texas Systems Cancer Center, Houston, TX
04/76-09/77
Assistant Professor, University of Texas Health Science Center, San Antonio, TX
04/76-09/79
Staff Physician, Audie Murphy VA Hospital, San Antonio, TX
09/77-10/79
Associate Professor, University of Texas Health Science Center, San Antonio, TX
10/79-06/82
Chairman, Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
07/82-10/06
Professor of Medicine, University of Washington, Seattle, WA
04/86-07/98
Head, Division of Oncology, University of Washington, Seattle, WA
07/97-10/06
Section Head, Division of Oncology, Solid Tumor, University of Washington/SCCA
07/82-10/06
Member, Fred Hutchinson Cancer Research Center, Seattle, WA
10/06-present Professor of Medicine, Arizona Cancer Center, University of Arizona, University Medical
Center, Tucson, Az
4/2007-7/2010 Director, Clinical Research Shared Services, Arizona Cancer Center, Tucson, AZ
8/11-present
Translational Clinical Research Training (Curriculum)
Honors and Responsibilities
1966
1974-1997
1975-present
1990-present
1996
1996
2000-2008
Rev 1.31.13
Alpha Omega Alpha
Chairman, Southwest Oncology Group Lung Cancer Committee
American Society of Clinical Oncology: Constitution & By-Laws Comm. (1979-84); Program
Comm. (1984, 89, 2002); Nominating Comm. (1989); Publications Comm. (1990-5)
Fellow, American Association for the Advancement of Science
Member, ACS Clinical Research, Cancer Control and Epidemiology Committee
Member, National Cancer Institute PDQ Adult Treatment Editorial Board
Chairman, Southwest Oncology Group Breast Cancer Committee
Page
1
Biographical Sketch Format Page
Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RL, Linden HM, Ellis GK, Schubert EK, Dunnwald LK,
Mankoff DA. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor
treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer
Res Treat, Published Online, February 1, 2007.
Linden HM, Stekhova SA, Link JM, Lawton T, Livingston RB, Gralow JR, Ellis GK, Peterson LM, Krohn KA,
Mankoff DA. Understanding resistance to hormonal therapy in estrogen avid breast cancer. Abstract No.
566 Poster Discussion presented at the meeting of the American Society of Clinical Oncology, Atlanta, GA
June 2-6, 2006.
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative Fluoroestradiol
Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment. J Clin Oncol. 2006
June 24(18):1-7.
Linden H M, Krohn KA, Livingston RB, Mankoff D. Monitoring Targeted Therapy: is fluorodexylucose (FDG)
Uptake a Marker of Early Response? Invited editorial that has been accepted for publication in Clinical
Cancer Research, American Association of Clinical Research, June 2006.
Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN Jr, Kelly K, Crowley J, Livingston R. Long-term
survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB nonsmall-cell lung cancer: a phase II SWOg study(S9504). Clin Lung Cancer. 2006 Sep;8(2):116-21
Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RL, Linden HM, Ellis GK, Schubert EK, Dunnwald LK,
Mankoff DA. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor
treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer
Res Treat, Published Online, February 1, 2007.
Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge, Jr. GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF,
Livingston RB, Martino S. Sequenced vs. simultaneous anthracycline and cyclophosphamide in high risk
stage I-II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20;25(6):656-661.
Pepe C, Hasan B, Winton T, Seymour L, Graham B, Livingston RB, Johnson D, Rigas J, Ding K, Shepard F.
Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup
Study JBR.10. J Clin Oncol. 2007 April 20:25(12):1553-1562Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB,
Piccart MJ, Castiglione M, Tu D, shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA,
Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group
MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone
receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J
Clin Oncol. 2007 May 20;25(15):2006-11.Moore HC, Green SJ, Gralow JR, Bearman, SI, Lew D, Barlow
WE,Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology
Group/Intergroup Study 9623. Intensive dose-dense compared with high-dose adjuvant chemotherapy for
high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol.2007
May 1;25(13):1677-82
Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu
D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast
cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. Epub 2008 Mar
10.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE,
Kurland BF, Schubert EK, Mankoff DA. Tumor Metabolism and Blood Flow Changes by position
Emission Tomography: Relation to survival in Patients Treated with Neoadjuvant Chemotherapy for
Locally Advanced Breast Cancer. J Clin Oncol. 2008 Jul 17 (E-Pub)
Swart R, Downey L, Lang J, Thompson P, Livingston R, Stopeck A. Breast Cancer. E-Medicine Chapter,
2009, In publication.
Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB,
Seymour L, Shepherd FA.Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell
lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008 Nov 1;26(31):5052-9. Epub
2008 Sep 22. PMID: 18809617 [PubMed - indexed for MEDLINE]
Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS.
Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients:
Retrospective
Analysis of Southwest Oncology Studies S8814/S8897. Clin Oncol. 2009 Mar 23. [Epub
Christine B Ambrosone, William E Barlow, Wanda Reynolds, Robert B Livingston, I-Tien Yeh, Ji-Yeob Choi,
1.31.13
Warren Davis, James M. Rae, Li Tang, Laura Hutchins, Peter Ravdin, Silvana Martino, C. Kent Osborne,
Martin Abeloff, Alan P Lyss, Daniel F Hayes, and Kathy S AlbainMyeloperoxidase Genotypes and
Enhanced Efficacy of Chemotherapy for Early Stage Breast Cancer in SWOG 8897. ahead of print]
PMID:
19307504 [PubMed - as supplied by publisher] JCO/2009/218669
Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D,
Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy- related
myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group
study (S0012). Breast Cancer Res Treat. 2009 Oct 23
Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN,
Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston
RB, Martino S, Osborne CK; Adjuvant chemotherapy and timing of tamoxifen in postmenopausal
patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised
controlled trial. For The Breast Cancer Intergroup of North AmericLancet. . [Epub ahead of print]PMID:
20004966 [PubMed - as supplied by publisher
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR,
Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast
cancer on chemotherapy: a retrospective analysis of a randomised trial. For The Breast Cancer Intergroup
of North America. Lancet Oncol. . [Epub ahead of print]
Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A,
Press MF. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does
not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin
Cancer Res. 2010 Feb 15;16(4):1281-8. Epub 2010 Feb 9.PMID: 20145176 [PubMed - in process]
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF,
Ravdin PM, Martino S, Lyss AP, Kent Osborne C, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB.
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in
SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Mar 23. [Epub ahead of print]
Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston
RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron
emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010
May 15;16(10):2803-10. Epub 2010 May 11.PMID: 20460489 [PubMed - in process]
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF,
Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene
Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free
Survival in SWOG 8897 Clinical Trial for Breast Cancer. Clin Cancer Res. 2010 Dec 15;16(24):61696176.PMID: 21169260 [PubMed - as supplied by publisher]
Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG,
Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N.Longer
therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun
3;362(22):2053-65.PMID: 20519679 [PubMed - indexed for MEDLINE]Free PMC ArticleGanz PA, Land
SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG,
Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual History and Qualityof-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the
NSABP B-30 Trial. J Clin Oncol. 2011 Feb 7.
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB.
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and
Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for
Inflammatory and Locally Advanced Breast Cancer: SWOG 0012. J Clin Oncol. 2011 Jan 10. [Epub ahead
of print]
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF,
Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients
1.31.13
undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose
uptake. Clin Cancer Res. 2011 Apr 15;17(8):2400-9. Epub 2011 Mar 1.
Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for
HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011 Aug 9.
Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis
W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB,
Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG
phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011 Jul 16.
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston
RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals
differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with
metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. Epub 2011 Jul 12.
Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for
HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment Volume 130, Number 1,
123-131
Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR,
Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and
Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. Oncologist. 2012 Jan 20.
Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X,
Mankoff DA, Linden HM.. Feasibility study of FDG PET as an indicator of early response to aromatase
inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012 Jun
25;2(1):34.
Combination Anastrozole And Fulvestrant In Metastatic Breast Cancer. Mehta RS, Barlow WE, Albain KS,
Vandenberg TA, Dakhil SE, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. N
Engl J Med. 2012 Aug 2;367(5):435-44. Doi: 10.1056/Nejmoa1201622.
C. Research Support
Neo-Adjuvant Therapy with Exemestane plus Pazopanib in Stage II and III ER+ Breast
Cancer
12/13/10-12/12/13
CA125627 (Gillies)
Imaging Biomarkers for Response to AntiCancer Therapy
The overall goal of this grant is to investigate MR imaging endpoints to predict and
monitor anti-cancer drug response. Two agents will be investigated, PX-866 a
PI3Kinase inhibitor and Sunitinib, a VEGFR inhibitor. Breast cancer tumor xenografts
with differential sensitivities to these drugs will be used as the model system. Primary
goals of this work are to: (1) determine which of these MR imaging biomarkers are
most useful for each drug; and (2) whether imaging biomarker responses can
differentiate between these drug classes. Aim 1 will investigate this by assessing tumor
and molecular responses to PX-866 and sunitinib. Aim 2 will assess the imaging
responses to these drugs to determine which imaging endpoints are most appropriate as
response biomarkers and Aim 3 will retrospectively analyze the pre-therapy images to
determine if any biomarker (or combination) would have been useful in predicting
response.
02/01/08-01/31/2013
1.31.13
5%
PI
GSK:
$400,950.00
5%
Co:P
I
NIH/NCI:
$250,000